Patents by Inventor Matityahu Fridkin
Matityahu Fridkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10072044Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.Type: GrantFiled: June 12, 2016Date of Patent: September 11, 2018Assignee: Yeda Research and Development Co. Ltd.Inventors: Michal Schwartz-Eisenbach, Matityahu Fridkin, Michal Cardon-Yaakov
-
Patent number: 9956295Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: July 22, 2016Date of Patent: May 1, 2018Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20170247429Abstract: The present invention relates to blood-brain barrier disrupting agents containing a modified serum albumin comprising serum albumin. The present invention further relates to pharmaceutical compositions comprising said agents and use thereof for the treatment of brain diseases and disorders.Type: ApplicationFiled: September 16, 2015Publication date: August 31, 2017Inventors: Itzik Cooper, David Guez, David Last, Yoram Shechter, Matityahu Fridkin, Yael Mardor
-
Publication number: 20170119847Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.Type: ApplicationFiled: December 28, 2016Publication date: May 4, 2017Applicant: Yeda Research and Development Co. Ltd.Inventors: Tsvee LAPIDOT, Alexander KALINKOVICH, Matityahu FRIDKIN
-
Patent number: 9567371Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.Type: GrantFiled: October 11, 2015Date of Patent: February 14, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Tsvee Lapidot, Alexander Kalinkovich, Matityahu Fridkin
-
Publication number: 20160324975Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: July 22, 2016Publication date: November 10, 2016Inventors: Yoram SHECHTER, Matityahu FRIDKIN, Haim TSUBERY
-
Patent number: 9480751Abstract: The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: GrantFiled: April 4, 2012Date of Patent: November 1, 2016Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yoram Shechter, Matityahu Fridkin
-
Publication number: 20160280739Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.Type: ApplicationFiled: June 12, 2016Publication date: September 29, 2016Applicant: Yeda Research and Development Co. Ltd.Inventors: Michal SCHWARTZ-EISENBACH, Matityahu FRIDKIN, Michal CARDON-YAAKOV
-
Patent number: 9433683Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: July 10, 2015Date of Patent: September 6, 2016Assignee: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Patent number: 9382293Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.Type: GrantFiled: March 14, 2013Date of Patent: July 5, 2016Assignee: Yeda Research and Development Co. Ltd.Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
-
Publication number: 20160122391Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.Type: ApplicationFiled: October 11, 2015Publication date: May 5, 2016Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Tsvee LAPIDOT, Alexander KALINKOVICH, Matityahu FRIDKIN
-
Publication number: 20160000927Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: July 10, 2015Publication date: January 7, 2016Inventors: Yoram SHECHTER, Matityahu FRIDKIN, Haim TSUBERY
-
Patent number: 9155780Abstract: The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells.Type: GrantFiled: February 10, 2010Date of Patent: October 13, 2015Assignee: Yeda Research and Development Co. Ltd.Inventors: Tsvee Lapidot, Alexander Kalinkovich, Matityahu Fridkin
-
Patent number: 9119883Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: August 26, 2014Date of Patent: September 1, 2015Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20150202310Abstract: The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: April 4, 2012Publication date: July 23, 2015Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTDInventors: Yoram Shechter, Matityahu Fridkin
-
Publication number: 20150093370Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Inventors: Yoram SHECHTER, Matityahu FRIDKIN
-
Publication number: 20150057219Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Publication number: 20150051151Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
-
Patent number: 8877709Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: January 2, 2014Date of Patent: November 4, 2014Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8735350Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: December 31, 2012Date of Patent: May 27, 2014Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery